Argenx is an immunology company that develops human antibody products for autoimmune diseases. The company's product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults. The company's pipeline products include efgartigimod, ARGX-119 targets congenital myasthenic syndrome and amyotrophic lateral sclerosis; ARGX-109, ARGX-121, ARGX-213 and ARGX-220. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenxis headquartered in Amsterdam, Noord-Holland, the Netherlands. The company reported revenues of (US Dollars) US$1,226.3 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$410.8 million in FY2022. The operating loss of the company was US$425.1 million in FY2023, compared to an operating loss of US$720.3 million in FY2022.